Laura Nisenbaum

, PhD

Executive Director, Drug Development, Alzheimer’s Drug Discovery Foundation

Laura Nisenbaum, PhD, is a proven scientific leader with 30 years of biotechnology and academia experience. She is the Executive Director of Drug Development at the Alzheimer’s Drug Discovery Foundation (ADDF). Prior to joining ADDF, Dr. Nisenbaum served as Senior Director of Aducanumab Biomarkers and Diagnostic Pathways at Biogen. Her time at Biogen followed 20 years of experience at Eli Lilly and Company in various roles including Asset Manager for Chorus, an autonomous early-phase clinical development unit within Lilly, Research Fellow and neuroscience lead in tailored therapeutics, translational medicine, and preclinical drug discovery. Prior to joining the biotechnology field, Dr. Nisenbaum received a Fulbright Scholarship to study in Cologne, Germany. She then completed her PhD in neuroscience in 1991 at the University of Pittsburgh and transitioned to industry after completing postdoctoral training at NIH, the University of Tennessee College of Medicine, and a faculty position in Physiology and Neurobiology at the University of Connecticut.

Read more

This Speaker's Sessions

Town Hall
Thursday Oct. 13
2:30–3:15 PM
Watch Replay
Now Live!

Investments in Innovation: The Path to New Alzheimer’s Treatments

Identifying and investing in innovative, impactful therapies is only possible when leading scientists and entrepreneurs are connected and have access to capital. Leaders of influential global investment organizations with a venture-minded approach to drug discovery will discuss their perspectives, resources, and funding opportunities to support and accelerate Alzheimer’s treatments. Key Question: What new drugs, technologies, and breakthrough innovations might benefit all of Us in the next 10 years, and how do we spark investment?

View SessionWatch Replay